Antibody Fragments Market

Antibody Fragments Market Size Analysis, By Specificity (Monoclonal Antibodies, Polyclonal Antibodies), By Type (FAB, scFv, sdAb, Others ), By Therapy (Monoclonal Antibodies, PAB, Pipeline), By Application (Cancer, Immunodeficiency, Others) & By Region – Global Market Insights 2022–2032

Analysis of Antibody Fragments Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Antibody Fragments Market Outlook (2022-2032)

The antibody fragments market is currently valued at USD 7.56 billion and is expected to grow at a compound annual growth rate (CAGR) of 5.9% during the forecast period. The market is to reach USD 13.41 Billion by 2032.

The increasing number of cancer cases around the world contributes to the antibody fragments market growth, which will eventually replace the full-length antibody. These are smaller and more easily penetrated, making them useful in the treatment of diseases like cancer, tumors, and COVID-19.

The growing geriatric population in developing economies such as India, Japan, Mexico, and China will boost demand for antibody fragments in the coming years. As second and third-generation technologies mature, demand for first-generation will decline. The COVID-19 pandemic boosted antibody fragments market demand because these are used in its treatment. With more diseases, the industry will continue to grow.

One of the key factors of the market is limiting the efficacy of antibody-targeted cancer therapies could be partial tumor penetration of the antibody-drug conjugate.

Report Attributes

Details

Market Size (2022)

USD 7.56 billion

Projected Market Value (2032)

USD 13.41 Billion

Global Market Growth Rate

5.9%

North America Market Share

50.0%

Japan Market Growth Rate

18.3%

Monoclonal Antibodies Market Share

95%

FAB Market Share

85%

Key Companies Profiled

  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Biogen Inc. and Eli Lilly and Co.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Infectious and Chronic Diseases are Becoming Pervasive

Chronic conditions have been steadily increasing around the world as a result of an ageing population and societal behaviour changes.

The rapid growth of the middle class is causing people to adopt a more sedentary and unhealthy lifestyle, which is causing an increase in diseases such as diabetes. Due to the rapid population growth, the emerging antibody fragments market is expected to bear the greatest patient burden.

Antibody Fragments Preferred Over Alternatives

With rising rates of cancer, infectious diseases, and, as a result, immune deficiencies, there will be greater demand for antibody fragments. Globally, there has been an increase in the geriatric population. When it comes to the application prospects of antibody fragments, the market is expected to boom. Antibody fragments are also expected to be preferred over full-chain antibodies due to lower manufacturing and purification costs.

Strict ICD-10 guidelines may limit the use of certain antibody fragments in the treatment of a specific disease. New developments in the clinical development of antibody fragments for some of the deadliest diseases can give a massive opportunity for the antibody fragments market over the forecast period.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

What Factors are Limiting Demand for Contract Manufacturing of Antibodies?

Global regulatory policies, cGMP, tightening inspection regimes, supply chain security issues across emerging markets, and R&D funding for some projects all have a significant impact on final product costs. Due to these factors, new entrants interested in biopharmaceutical contract manufacturing face financial challenges in the market for antibody fragments.

One of the major constraints is the high investment required for antibody fragments. Much of it has gone to tax havens like Ireland and Singapore, as well as emerging markets. Many businesses have reported a significant skills gap between qualified professionals and the current workforce. Many governments want to encourage the development of a mainstream biotech industry similar to the one in the United States, but progress has been slow. In most emerging countries, the growth of the antibody fragments industry has been hampered by insufficient funding, poor planning, and a scarcity of experienced individuals.

Segmentation Insights

Monoclonal Antibodies to Lead

The monoclonal antibodies segment had the highest revenue share of more than 95.0%. Monoclonal antibodies (mAbs) are a significant class of therapeutic agents used in the treatment of various types of cancer. However, the use of conventional mAbs in anticancer immunotherapies may encounter a number of limitations, including adverse effects and insufficient efficacy.

The use of antibody fragments in cancer therapy has received more attention than any other therapeutic application. However, its use in the development of pharmacological tools for the treatment of autoimmune diseases and infectious diseases is rapidly increasing.

Polyclonal antibodies (pAbs) have higher specificity and flexibility than monoclonal antibodies and are, therefore, superior for clinical applications. Researchers have had difficulty using pAbs antibody reagents because they are inconsistent in nature and interfere with their research studies. These are some of the factors that may limit the use of polyclonal antibodies, thereby limiting the market's overall growth.

FAB to Capture the Highest Market share

As the first generation of antibody fragments, the FAB segment captured the highest revenue share of more than 85.0% in 2021. Due to the rising prevalence of cancer, infectious diseases, and autoimmune diseases, there is a high demand for F(ab) fragments, which is fueling segment growth.

The approval and commercialization of novel therapies to aid in the treatment of life-threatening diseases are expected to drive segment growth. However, as molecule quality improves, market share is expected to decline over time with the introduction of second and third-generation molecules of antibody fragments.

Single-chain variable fragments (scFvs) are expected to grow at the fastest rate during the forecast period. They have several advantages over mAbs, including heterologous production, multivalency, low molecular weight, and multimeric form.

It is used in a variety of medical applications, such as bioimaging and targeted therapy. The scFv phage display antibody technology has quickly become one of the most popular ways to create recombinant antibodies. These factors are influencing segment growth.

Insights into Therapy Segment

The Ranibizumab segment had the highest revenue share. Ranibizumab is a monoclonal antibody fragment produced by recombinant DNA technology in E.coli cells.

In the pharmaceutical industry, it is available as an injection and is used to treat visual impairment caused by diabetic macular edoema, neovascular (wet) age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), and other conditions.

Several academies and companies are working to understand the challenges and opportunities that could influence Ranibizumab research and development. Beovu (brolucizumab-dbll) is expected to grow the fastest during the forecast period. It is a monoclonal single-chain Fv antibody fragment used for intravitreal injection in the eye.

Insights into Application Segment

Due to the increasing prevalence of the disease globally, the immunodeficiency segment held the largest revenue share of more than 85.0% in 2021. Increased collaborations and partnerships for the development of novel therapies for immunocompromised patients are expected to support segment growth.

During the forecast period, the cancer segment is expected to grow the fastest. The high global prevalence of cancer is one of the major factors driving market growth over the forecast period. A high cancer incidence is expected to drive the adoption of novel and effective cancer diagnostic and therapeutic methods.

The other segment, which includes chronic diseases like age-related macular degeneration (AMD) and infectious diseases like HIV/AIDS and influenza, is expected to grow significantly in the coming years. Furthermore, key market participants are working on antibody fragments for eye disorders that are in the preclinical and clinical development stages.

Country Insights

North America Insights

North America dominated the antibody fragments market with a revenue share of more than 50.0%, owing to the expansion of regional pharmaceutical industries, which resulted in rising demand for antibody fragments. The rising prevalence of immunodeficiency diseases and cancer has increased the demand for antibody fragments for research purposes.

  • What makes the United States the largest market for contract manufacturing of antibodies?

The United States dominates the North American region, with a total market share of 89.5%, and is expected to grow rapidly throughout the forecast period.

Rising R&D activities, the presence of leading market players, an established healthcare system, an increase in clinical trial numbers, and increased government interest in biologics are driving demand for antibody fragments.

Asia Pacific Insights

The developing antibody fragments market in Asia Pacific is expected to drive significant growth over the forecast period. Due to the increased emphasis on the biologics manufacturing sector, India and China are expected to dominate the market for antibody fragments.

  • What makes Japan an emerging market for contract manufacturing of antibodies?

Japan is expected to hold an 8.9% share of the East Asian market, with a CAGR of around 18.3%. Advanced healthcare infrastructure, a growing interest in overseas expansion by Asian CDMOs, and massive-scale up capacities and capabilities are major factors contributing to the country's antibody fragments market growth.

  • Why is India a growing market for contract manufacturing of antibodies?

With a 30% market share, India to dominate the South Asian market for antibody fragments.

The low labour cost, abundant raw material supply, significant manufacturing expertise, expanding advanced R&D facilities, and presence of major international and domestic players are driving demand for antibody fragments.

Europe Insights

  • Why is the United Kingdom a profitable market for contract manufacturing of antibodies in Europe?

With a 26.8% share in 2021, the United Kingdom dominates the European market for antibody fragments.

The increasing demand for antibody-based therapeutics, the favourable safety profile of antibodies related to therapeutics, increased production capabilities, and the presence of prominent players are driving demand for antibody fragments.

Comparative View of Adjacent Antibody Fragments Market 

Antibody Fragments Market:

Attributes

Antibody Fragments Market

CAGR

5.9%

Market Value

(2027)

USD 10.07 Billion

Growth Factor

Infectious and chronic diseases are becoming more common.

Opportunity

The growing geriatric population in developing economies will boost industrial demand in the coming years.

Key Trends

Antibody Fragments Preferentially Over Alternatives

Antibody Production Market:

Attributes

Antibody Production Market

CAGR

13.5%

Market Value

(2027)

USD 29.80 Billion

Growth Factor

A major factor driving growth is the increasing focus of biopharmaceutical and biotechnology companies on the production of antibody therapeutics.

Opportunity

A focus on R&D is an essential strategy for driving the company's long-term growth.

Key Trends

The production of therapeutic antibodies is increasing, which will drive market growth during the forecast period.

Research Antibodies Market:

Attributes

Research Antibodies Market

CAGR

4.93%

Market Value

(2027)

USD 1.88 Billion

Growth Factor

The increased demand for high-quality antibodies for reproducible research is one of the key factors driving market growth.

Opportunity

The rising demand for protein therapies and personalised medicines is creating new market opportunities and promising lucrative growth for market participants.

Key Trends

The market is expanding as a result of the expanding landscape of proteomics and genomics research, as well as increased research and development efforts in the life sciences domain.

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Competitive Landscape

Key antibody fragments market players are focusing on expanding into new markets and developing new products. Key manufacturers' expansion strategy, new product launches and approvals, agreements, partnerships, collaborations, and developed distribution channels such as online sales are strengthening their market presence.

Recent Development

Date

Company Name

Strategy

Details

March 2021

Wuxi Biologics

Agreement

Wuxi Biologics entered into an equity agreement with Pfizer in March 2021 to acquire its biologics drug substance and drug manufacturing facilities in China, as well as the workforce. This acquisition will assist Wuxi in expanding its drug substance and drug product portfolio in the Chinese market.

March 2021

AGC Biologics

Manufacturing Facility

AGC Biologics opened a new manufacturing facility in Italy in March 2021 to expand its manufacturing capacity and implement viral vector suspension capabilities. Such expansions will help the company strengthen its position in the CDMO market.

August 2020

Avid Bioservices

Contract

Avid Bioservices signed a contract with Mapp Biopharmaceutical Inc. in August 2020 for the clinical development of novel human monoclonal antiviral antibodies.

January 2020

Adaptimmune Therapeutics plc

Collaboration

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, announced a collaboration agreement with Astellas Pharma Inc., a Japanese pharmaceutical company, in January 2020, to develop and commercialise TCR T cell therapies and stem-cell-derived allogeneic chimeric antigen receptor (CAR)-T to treat a large patient population suffering from immunodeficiency caused by various types of cancer, including solid tumours.

May 2020

Centre for Cellular and Molecular Biology

Collaboration

The Centre for Cellular and Molecular Biology and the University of Hyderabad announced collaboration with Vins Bioproducts Ltd. in May 2020 to develop immunotherapy based on antibody fragments for COVID-19 treatment.

March 2021

Amgen Inc.

Acquisitions

Amgen Inc. announced the USD 1.9 billion acquisition of Five Prime Therapeutics, a clinical-stage biotechnology company, and its lead candidate, bemarituzumab, for gastric cancer, in March 2021, in order to broaden the scope of targeted cancer therapies and immuno-oncology.

March 2021

Amgen Inc.

Acquisitions

Amgen Inc. announced the USD 720 million acquisition of Rodeo Therapeutics, a privately held biopharmaceutical company, in March 2021 to develop small-molecule therapies for the regeneration and repair of multiple tissues.

Key Segments  

  • By Specificity

    • Monoclonal Antibodies
    • Polyclonal Antibodies
  • By Type

    • FAB
    • scFv
    • sdAb
    • Others
  • By Therapy

    • Monoclonal Antibodies
    • PAB
    • Pipeline
  • By Application

    • Cancer
    • Immunodeficiency
    • Others
  • By Region

    • North America
    • Latin America
    • Asia Pacific
    • MEA
    • Europe

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Specificity

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Specificity, 2017-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Specificity, 2022-2032

        5.3.1. Monoclonal Antibodies

        5.3.2. Polyclonal Antibodies

    5.4. Y-o-Y Growth Trend Analysis By Specificity, 2017-2021

    5.5. Absolute $ Opportunity Analysis By Specificity, 2022-2032

6. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Type, 2017-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Type, 2022-2032

        6.3.1. FAB

        6.3.2. scFv

        6.3.3. sdAb

        6.3.4. Others

    6.4. Y-o-Y Growth Trend Analysis By Type, 2017-2021

    6.5. Absolute $ Opportunity Analysis By Type, 2022-2032

7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Therapy

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By Therapy , 2017-2021

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Therapy , 2022-2032

        7.3.1. Monoclonal Antibodies

            7.3.1.1. Praxbind - Idarucizumab

            7.3.1.2. Ranibizumab - Lucentis

            7.3.1.3. Certolizumab Pegol -Cimzia

            7.3.1.4. Iodine (1311) Metuximab/ Licartin

            7.3.1.5. Beovu - Brolucizumab-dbll

            7.3.1.6. Cablivi - Caplacizumab-yhdp

            7.3.1.7. Blinatumomab

        7.3.2. PAB

            7.3.2.1. CroFab

            7.3.2.2. Anavip

            7.3.2.3. Anascorp

            7.3.2.4. Botulism Antitoxin Heptavalent - HBAT

            7.3.2.5. Digibind

            7.3.2.6. DigiFab

        7.3.3. Pipeline

            7.3.3.1. AFM13

            7.3.3.2. HPN-424

            7.3.3.3. MGD007

            7.3.3.4. Tebotelimab - MGD013

            7.3.3.5. Bentracimab - PB2452

            7.3.3.6. Flotetuzumab - MGD006

            7.3.3.7. AK104

            7.3.3.8. Ozoralizumab

            7.3.3.9. Sonelokimab - ALX0761

    7.4. Y-o-Y Growth Trend Analysis By Therapy , 2017-2021

    7.5. Absolute $ Opportunity Analysis By Therapy , 2022-2032

8. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Application

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Mn) Analysis By Application, 2017-2021

    8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Application, 2022-2032

        8.3.1. Cancer

        8.3.2. Immunodeficiency

        8.3.3. Others

    8.4. Y-o-Y Growth Trend Analysis By Application, 2017-2021

    8.5. Absolute $ Opportunity Analysis By Application, 2022-2032

9. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021

    9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. Asia Pacific

        9.3.5. MEA

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. U.S.

            10.2.1.2. Canada

        10.2.2. By Specificity

        10.2.3. By Type

        10.2.4. By Therapy

        10.2.5. By Application

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Specificity

        10.3.3. By Type

        10.3.4. By Therapy

        10.3.5. By Application

    10.4. Key Takeaways

11. Latin America Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Specificity

        11.2.3. By Type

        11.2.4. By Therapy

        11.2.5. By Application

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Specificity

        11.3.3. By Type

        11.3.4. By Therapy

        11.3.5. By Application

    11.4. Key Takeaways

12. Europe Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. U.K.

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Europe

        12.2.2. By Specificity

        12.2.3. By Type

        12.2.4. By Therapy

        12.2.5. By Application

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Specificity

        12.3.3. By Type

        12.3.4. By Therapy

        12.3.5. By Application

    12.4. Key Takeaways

13. Asia Pacific Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

            13.2.1.4. Singapore

            13.2.1.5. Thailand

            13.2.1.6. Indonesia

            13.2.1.7. Australia

            13.2.1.8. New Zealand

            13.2.1.9. Rest of Asia Pacific

        13.2.2. By Specificity

        13.2.3. By Type

        13.2.4. By Therapy

        13.2.5. By Application

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Specificity

        13.3.3. By Type

        13.3.4. By Therapy

        13.3.5. By Application

    13.4. Key Takeaways

14. MEA Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Specificity

        14.2.3. By Type

        14.2.4. By Therapy

        14.2.5. By Application

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Specificity

        14.3.3. By Type

        14.3.4. By Therapy

        14.3.5. By Application

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. U.S.

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2021

            15.1.2.1. By Specificity

            15.1.2.2. By Type

            15.1.2.3. By Therapy

            15.1.2.4. By Application

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2021

            15.2.2.1. By Specificity

            15.2.2.2. By Type

            15.2.2.3. By Therapy

            15.2.2.4. By Application

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2021

            15.3.2.1. By Specificity

            15.3.2.2. By Type

            15.3.2.3. By Therapy

            15.3.2.4. By Application

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2021

            15.4.2.1. By Specificity

            15.4.2.2. By Type

            15.4.2.3. By Therapy

            15.4.2.4. By Application

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2021

            15.5.2.1. By Specificity

            15.5.2.2. By Type

            15.5.2.3. By Therapy

            15.5.2.4. By Application

    15.6. U.K.

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2021

            15.6.2.1. By Specificity

            15.6.2.2. By Type

            15.6.2.3. By Therapy

            15.6.2.4. By Application

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2021

            15.7.2.1. By Specificity

            15.7.2.2. By Type

            15.7.2.3. By Therapy

            15.7.2.4. By Application

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2021

            15.8.2.1. By Specificity

            15.8.2.2. By Type

            15.8.2.3. By Therapy

            15.8.2.4. By Application

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2021

            15.9.2.1. By Specificity

            15.9.2.2. By Type

            15.9.2.3. By Therapy

            15.9.2.4. By Application

    15.10. China

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2021

            15.10.2.1. By Specificity

            15.10.2.2. By Type

            15.10.2.3. By Therapy

            15.10.2.4. By Application

    15.11. Japan

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2021

            15.11.2.1. By Specificity

            15.11.2.2. By Type

            15.11.2.3. By Therapy

            15.11.2.4. By Application

    15.12. South Korea

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2021

            15.12.2.1. By Specificity

            15.12.2.2. By Type

            15.12.2.3. By Therapy

            15.12.2.4. By Application

    15.13. Singapore

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2021

            15.13.2.1. By Specificity

            15.13.2.2. By Type

            15.13.2.3. By Therapy

            15.13.2.4. By Application

    15.14. Thailand

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2021

            15.14.2.1. By Specificity

            15.14.2.2. By Type

            15.14.2.3. By Therapy

            15.14.2.4. By Application

    15.15. Indonesia

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2021

            15.15.2.1. By Specificity

            15.15.2.2. By Type

            15.15.2.3. By Therapy

            15.15.2.4. By Application

    15.16. Australia

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2021

            15.16.2.1. By Specificity

            15.16.2.2. By Type

            15.16.2.3. By Therapy

            15.16.2.4. By Application

    15.17. New Zealand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2021

            15.17.2.1. By Specificity

            15.17.2.2. By Type

            15.17.2.3. By Therapy

            15.17.2.4. By Application

    15.18. GCC Countries

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2021

            15.18.2.1. By Specificity

            15.18.2.2. By Type

            15.18.2.3. By Therapy

            15.18.2.4. By Application

    15.19. South Africa

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2021

            15.19.2.1. By Specificity

            15.19.2.2. By Type

            15.19.2.3. By Therapy

            15.19.2.4. By Application

    15.20. Israel

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2021

            15.20.2.1. By Specificity

            15.20.2.2. By Type

            15.20.2.3. By Therapy

            15.20.2.4. By Application

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Specificity

        16.3.3. By Type

        16.3.4. By Therapy

        16.3.5. By Application

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Pfizer Inc.

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Sanofi

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Novartis AG

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Genentech, Inc.

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. AbbVie Inc.

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Bristol-Myers Squibb Company

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Johnson & Johnson Private Limited

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Lilly

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. F. Hoffmann-La Roche Ltd

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Takeda Pharmaceutical Company Limited

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Don't Need a Global Report?

save 40%! on Country & Region specific reports

List Of Table

Table 01: Global Market Value (US$ Mn) Forecast by Region, 2017-2032

Table 02: Global Market Value (US$ Mn) Forecast by Specificity, 2017-2032

Table 03: Global Market Value (US$ Mn) Forecast by Type, 2017-2032

Table 04: Global Market Value (US$ Mn) Forecast by Therapy , 2017-2032

Table 05: Global Market Value (US$ Mn) Forecast by Application, 2017-2032

Table 06: North America Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 07: North America Market Value (US$ Mn) Forecast by Specificity, 2017-2032

Table 08: North America Market Value (US$ Mn) Forecast by Type, 2017-2032

Table 09: North America Market Value (US$ Mn) Forecast by Therapy , 2017-2032

Table 10: North America Market Value (US$ Mn) Forecast by Application, 2017-2032

Table 11: Latin America Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 12: Latin America Market Value (US$ Mn) Forecast by Specificity, 2017-2032

Table 13: Latin America Market Value (US$ Mn) Forecast by Type, 2017-2032

Table 14: Latin America Market Value (US$ Mn) Forecast by Therapy , 2017-2032

Table 15: Latin America Market Value (US$ Mn) Forecast by Application, 2017-2032

Table 16: Europe Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 17: Europe Market Value (US$ Mn) Forecast by Specificity, 2017-2032

Table 18: Europe Market Value (US$ Mn) Forecast by Type, 2017-2032

Table 19: Europez Market Value (US$ Mn) Forecast by Therapy , 2017-2032

Table 20: Europe Market Value (US$ Mn) Forecast by Application, 2017-2032

Table 21: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 22: Asia Pacific Market Value (US$ Mn) Forecast by Specificity, 2017-2032

Table 23: Asia Pacific Market Value (US$ Mn) Forecast by Type, 2017-2032

Table 24: Asia Pacific Market Value (US$ Mn) Forecast by Therapy , 2017-2032

Table 25: Asia Pacific Market Value (US$ Mn) Forecast by Application, 2017-2032

Table 26: MEA Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 27: MEA Market Value (US$ Mn) Forecast by Specificity, 2017-2032

Table 28: MEA Market Value (US$ Mn) Forecast by Type, 2017-2032

Table 29: MEA Market Value (US$ Mn) Forecast by Therapy , 2017-2032

Table 30: MEA Market Value (US$ Mn) Forecast by Application, 2017-2032

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

List Of Figures

Figure 01: Global Market Value (US$ Mn) by Specificity, 2022-2032

Figure 02: Global Market Value (US$ Mn) by Type, 2022-2032

Figure 03: Global Market Value (US$ Mn) by Therapy , 2022-2032

Figure 04: Global Market Value (US$ Mn) by Application, 2022-2032

Figure 05: Global Market Value (US$ Mn) by Region, 2022-2032

Figure 06: Global Market Value (US$ Mn) Analysis by Region, 2017-2032

Figure 07: Global Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 08: Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 09: Global Market Value (US$ Mn) Analysis by Specificity, 2017-2032

Figure 10: Global Market Value Share (%) and BPS Analysis by Specificity, 2022-2032

Figure 11: Global Market Y-o-Y Growth (%) Projections by Specificity, 2022-2032

Figure 12: Global Market Value (US$ Mn) Analysis by Type, 2017-2032

Figure 13: Global Market Value Share (%) and BPS Analysis by Type, 2022-2032

Figure 14: Global Market Y-o-Y Growth (%) Projections by Type, 2022-2032

Figure 15: Global Market Value (US$ Mn) Analysis by Therapy , 2017-2032

Figure 16: Global Market Value Share (%) and BPS Analysis by Therapy , 2022-2032

Figure 17: Global Market Y-o-Y Growth (%) Projections by Therapy , 2022-2032

Figure 18: Global Market Value (US$ Mn) Analysis by Application, 2017-2032

Figure 19: Global Market Value Share (%) and BPS Analysis by Application, 2022-2032

Figure 20: Global Market Y-o-Y Growth (%) Projections by Application, 2022-2032

Figure 21: Global Market Attractiveness by Specificity, 2022-2032

Figure 22: Global Market Attractiveness by Type, 2022-2032

Figure 23: Global Market Attractiveness by Therapy , 2022-2032

Figure 24: Global Market Attractiveness by Application, 2022-2032

Figure 25: Global Market Attractiveness by Region, 2022-2032

Figure 26: North America Market Value (US$ Mn) by Specificity, 2022-2032

Figure 27: North America Market Value (US$ Mn) by Type, 2022-2032

Figure 28: North America Market Value (US$ Mn) by Therapy , 2022-2032

Figure 29: North America Market Value (US$ Mn) by Application, 2022-2032

Figure 30: North America Market Value (US$ Mn) by Country, 2022-2032

Figure 31: North America Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 34: North America Market Value (US$ Mn) Analysis by Specificity, 2017-2032

Figure 35: North America Market Value Share (%) and BPS Analysis by Specificity, 2022-2032

Figure 36: North America Market Y-o-Y Growth (%) Projections by Specificity, 2022-2032

Figure 37: North America Market Value (US$ Mn) Analysis by Type, 2017-2032

Figure 38: North America Market Value Share (%) and BPS Analysis by Type, 2022-2032

Figure 39: North America Market Y-o-Y Growth (%) Projections by Type, 2022-2032

Figure 40: North America Market Value (US$ Mn) Analysis by Therapy , 2017-2032

Figure 41: North America Market Value Share (%) and BPS Analysis by Therapy , 2022-2032

Figure 42: North America Market Y-o-Y Growth (%) Projections by Therapy , 2022-2032

Figure 43: North America Market Value (US$ Mn) Analysis by Application, 2017-2032

Figure 44: North America Market Value Share (%) and BPS Analysis by Application, 2022-2032

Figure 45: North America Market Y-o-Y Growth (%) Projections by Application, 2022-2032

Figure 46: North America Market Attractiveness by Specificity, 2022-2032

Figure 47: North America Market Attractiveness by Type, 2022-2032

Figure 48: North America Market Attractiveness by Therapy , 2022-2032

Figure 49: North America Market Attractiveness by Application, 2022-2032

Figure 50: North America Market Attractiveness by Country, 2022-2032

Figure 51: Latin America Market Value (US$ Mn) by Specificity, 2022-2032

Figure 52: Latin America Market Value (US$ Mn) by Type, 2022-2032

Figure 53: Latin America Market Value (US$ Mn) by Therapy , 2022-2032

Figure 54: Latin America Market Value (US$ Mn) by Application, 2022-2032

Figure 55: Latin America Market Value (US$ Mn) by Country, 2022-2032

Figure 56: Latin America Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 59: Latin America Market Value (US$ Mn) Analysis by Specificity, 2017-2032

Figure 60: Latin America Market Value Share (%) and BPS Analysis by Specificity, 2022-2032

Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Specificity, 2022-2032

Figure 62: Latin America Market Value (US$ Mn) Analysis by Type, 2017-2032

Figure 63: Latin America Market Value Share (%) and BPS Analysis by Type, 2022-2032

Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Type, 2022-2032

Figure 65: Latin America Market Value (US$ Mn) Analysis by Therapy , 2017-2032

Figure 66: Latin America Market Value Share (%) and BPS Analysis by Therapy , 2022-2032

Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Therapy , 2022-2032

Figure 68: Latin America Market Value (US$ Mn) Analysis by Application, 2017-2032

Figure 69: Latin America Market Value Share (%) and BPS Analysis by Application, 2022-2032

Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Application, 2022-2032

Figure 71: Latin America Market Attractiveness by Specificity, 2022-2032

Figure 72: Latin America Market Attractiveness by Type, 2022-2032

Figure 73: Latin America Market Attractiveness by Therapy , 2022-2032

Figure 74: Latin America Market Attractiveness by Application, 2022-2032

Figure 75: Latin America Market Attractiveness by Country, 2022-2032

Figure 76: Europe Market Value (US$ Mn) by Specificity, 2022-2032

Figure 77: Europe Market Value (US$ Mn) by Type, 2022-2032

Figure 78: Europe Market Value (US$ Mn) by Therapy , 2022-2032

Figure 79: Europe Market Value (US$ Mn) by Application, 2022-2032

Figure 80: Europe Market Value (US$ Mn) by Country, 2022-2032

Figure 81: Europe Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 84: Europe Market Value (US$ Mn) Analysis by Specificity, 2017-2032

Figure 85: Europe Market Value Share (%) and BPS Analysis by Specificity, 2022-2032

Figure 86: Europe Market Y-o-Y Growth (%) Projections by Specificity, 2022-2032

Figure 87: Europe Market Value (US$ Mn) Analysis by Type, 2017-2032

Figure 88: Europe Market Value Share (%) and BPS Analysis by Type, 2022-2032

Figure 89: Europe Market Y-o-Y Growth (%) Projections by Type, 2022-2032

Figure 90: Europe Market Value (US$ Mn) Analysis by Therapy , 2017-2032

Figure 91: Europe Market Value Share (%) and BPS Analysis by Therapy , 2022-2032

Figure 92: Europe Market Y-o-Y Growth (%) Projections by Therapy , 2022-2032

Figure 93: Europe Market Value (US$ Mn) Analysis by Application, 2017-2032

Figure 94: Europe Market Value Share (%) and BPS Analysis by Application, 2022-2032

Figure 95: Europe Market Y-o-Y Growth (%) Projections by Application, 2022-2032

Figure 96: Europe Market Attractiveness by Specificity, 2022-2032

Figure 97: Europe Market Attractiveness by Type, 2022-2032

Figure 98: Europe Market Attractiveness by Therapy , 2022-2032

Figure 99: Europe Market Attractiveness by Application, 2022-2032

Figure 100: Europe Market Attractiveness by Country, 2022-2032

Figure 101: Asia Pacific Market Value (US$ Mn) by Specificity, 2022-2032

Figure 102: Asia Pacific Market Value (US$ Mn) by Type, 2022-2032

Figure 103: Asia Pacific Market Value (US$ Mn) by Therapy , 2022-2032

Figure 104: Asia Pacific Market Value (US$ Mn) by Application, 2022-2032

Figure 105: Asia Pacific Market Value (US$ Mn) by Country, 2022-2032

Figure 106: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 107: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 108: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 109: Asia Pacific Market Value (US$ Mn) Analysis by Specificity, 2017-2032

Figure 110: Asia Pacific Market Value Share (%) and BPS Analysis by Specificity, 2022-2032

Figure 111: Asia Pacific Market Y-o-Y Growth (%) Projections by Specificity, 2022-2032

Figure 112: Asia Pacific Market Value (US$ Mn) Analysis by Type, 2017-2032

Figure 113: Asia Pacific Market Value Share (%) and BPS Analysis by Type, 2022-2032

Figure 114: Asia Pacific Market Y-o-Y Growth (%) Projections by Type, 2022-2032

Figure 115: Asia Pacific Market Value (US$ Mn) Analysis by Therapy , 2017-2032

Figure 116: Asia Pacific Market Value Share (%) and BPS Analysis by Therapy , 2022-2032

Figure 117: Asia Pacific Market Y-o-Y Growth (%) Projections by Therapy , 2022-2032

Figure 118: Asia Pacific Market Value (US$ Mn) Analysis by Application, 2017-2032

Figure 119: Asia Pacific Market Value Share (%) and BPS Analysis by Application, 2022-2032

Figure 120: Asia Pacific Market Y-o-Y Growth (%) Projections by Application, 2022-2032

Figure 121: Asia Pacific Market Attractiveness by Specificity, 2022-2032

Figure 122: Asia Pacific Market Attractiveness by Type, 2022-2032

Figure 123: Asia Pacific Market Attractiveness by Therapy , 2022-2032

Figure 124: Asia Pacific Market Attractiveness by Application, 2022-2032

Figure 125: Asia Pacific Market Attractiveness by Country, 2022-2032

Figure 126: MEA Market Value (US$ Mn) by Specificity, 2022-2032

Figure 127: MEA Market Value (US$ Mn) by Type, 2022-2032

Figure 128: MEA Market Value (US$ Mn) by Therapy , 2022-2032

Figure 129: MEA Market Value (US$ Mn) by Application, 2022-2032

Figure 130: MEA Market Value (US$ Mn) by Country, 2022-2032

Figure 131: MEA Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 132: MEA Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 133: MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 134: MEA Market Value (US$ Mn) Analysis by Specificity, 2017-2032

Figure 135: MEA Market Value Share (%) and BPS Analysis by Specificity, 2022-2032

Figure 136: MEA Market Y-o-Y Growth (%) Projections by Specificity, 2022-2032

Figure 137: MEA Market Value (US$ Mn) Analysis by Type, 2017-2032

Figure 138: MEA Market Value Share (%) and BPS Analysis by Type, 2022-2032

Figure 139: MEA Market Y-o-Y Growth (%) Projections by Type, 2022-2032

Figure 140: MEA Market Value (US$ Mn) Analysis by Therapy , 2017-2032

Figure 141: MEA Market Value Share (%) and BPS Analysis by Therapy , 2022-2032

Figure 142: MEA Market Y-o-Y Growth (%) Projections by Therapy , 2022-2032

Figure 143: MEA Market Value (US$ Mn) Analysis by Application, 2017-2032

Figure 144: MEA Market Value Share (%) and BPS Analysis by Application, 2022-2032

Figure 145: MEA Market Y-o-Y Growth (%) Projections by Application, 2022-2032

Figure 146: MEA Market Attractiveness by Specificity, 2022-2032

Figure 147: MEA Market Attractiveness by Type, 2022-2032

Figure 148: MEA Market Attractiveness by Therapy , 2022-2032

Figure 149: MEA Market Attractiveness by Application, 2022-2032

Figure 150: MEA Market Attractiveness by Country, 2022-2032

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

- FAQs -

What is the Current Antibody Fragments Market Size?

The antibody fragments market size has currently valued at US$ 7.56 Million

How is the Antibody Fragments Market Growing?

The antibody fragments market is predicted to register a CAGR of 5.9% through 2032.

What is the Future Scope of Growth for the Antibody Fragments Market?

The antibody fragments market is expected to surpass US$ 13.41 Million by 2032.

Which Region Holds the Highest Revenue Potential in the Antibody Fragments Market?

The North American antibody fragments market holds the highest revenue potential.

Antibody Fragments Market

Schedule a Call